NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer

Ventus and Genentech partner for small-molecule medicine discovery

Acquisition strengthens Aspire Pharma’s strategic portfolio

Alkermes has agreed to acquire Avadel Pharmaceuticals for up to $20 per share in cash, valuing Avadel at $2.1bn.

NanoViricides reports antiviral activity of NV-387 against measles in preclinical studies